CTOs on the Move

Hendricks Regional Health

www.hendricks.org

 
Hendricks Regional Health is a non-profit, multi-specialty healthcare organization caring for communities in the Western and Central suburban area of Indianapolis since 1962, with a full-service hospital in Danville and medical buildings in Avon, Bainbridge, Brownsburg, Plainfield and Lizton. In December 2017, we will be opening our second hospital to serve the growing needs of the Brownsburg area.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Todd Davis
Executive Director of Information Systems Profile

Similar Companies

Better Health Group

Better Health Group is a national primary care platform that enables providers to shift focus to value-based care. They take a proactive approach by focusing on preventing disease rather than just treating symptoms.

Saint Margaret Mercy Healthcare Centers

Saint Margaret Mercy Healthcare Centers is a Hammond, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Train for Compliance

Train for Compliance is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthcare South Pc

Healthcare South Pc is a Pembroke, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.